We are live on ! Find out more
RCI

Ridgeback Capital Investments Portfolio holdings

AUM $560K
This Fund
S&P 500
This Quarter Est. Return
+3.48%
1 Year Est. Return
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$79.1M
AUM Growth
Cap. Flow
+$76.5M
Cap. Flow %
96.67%
Top 10 Hldgs %
100%
Holding
5
New
5
Increased
Reduced
Closed

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
SGMO
1
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$40.3M 50.91%
+2,900,000
New +$33.4M
CLDX icon
2
Celldex Therapeutics
CLDX
$2.8B
$24.8M 31.36%
+68,333
New +$26.3M
STML
3
DELISTED
Stemline Therapeutics, Inc.
STML
$9.93M 12.55%
+506,699
New +$13.5M
ARWR icon
4
Arrowhead Research
ARWR
$12.1B
$3.03M 3.83%
+279,361
New +$2.23M
GERN icon
5
Geron
GERN
$949M
$1.07M 1.35%
+238,050
New +$1.02M

Similar funds

Ridgeback Capital Investments's Q4 2013 Portfolio in Review

Q4 2013 is the first quarter with a 13F filing on record for Ridgeback Capital Investments, which disclosed 5 positions worth $79.1M. Its ten largest holdings account for 100% of the portfolio.

Its largest position is SANGAMO THERAPEUTICS INC: 2,900,000 shares worth $40.3M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets.

  • Ridgeback Capital Investments's largest Q4 2013 buy was SANGAMO THERAPEUTICS INC: 2,900,000 shares worth $40.3M.
  • Ridgeback Capital Investments's ten largest holdings make up 100% of its $79.1M portfolio in Q4 2013.
  • Ridgeback Capital Investments disclosed 5 positions in Q4 2013, its first 13F filing on record.

Based on Ridgeback Capital Investments's 13F filing for Q4 2013, filed 15 May 2014.